US · Healthcare · Health Information Services
EPS came in at -0.15 against a street estimate of -0.23 — a beat of 34.8%.
Analysts rate Teladoc Inc a hold (6 buy, 17 hold, 0 sell out of 23) with an average price target of $7.47.
MIXED Teladoc beat Q3 expectations and raised 2026 revenue and EBITDA guidance, but BetterHelp cash-pay declines persist as insurance expansion requires investment. Q3 FY26 International Integrated Care grew double digits, while BetterHelp continued shifting U.S. demand from cash pay toward insurance. Analysts focused heavily on BetterHelp’s insurance ramp, cash-pay decline, therapist capacity and future margins. Management emphasized execution progress while warning that the transition will pressure near-term revenue and profitability. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.93% |
| Vanguard Portfolio Management, LLC | 6.98% |
| Point72 Asset Management, L.P. | 4.54% |
| Renaissance Technologies Corp | 4.44% |
| Voss Capital LLC | 4.43% |
| Vanguard Capital Management, LLC | 4.38% |
| Dimensional Fund Advisors, Inc. | 4.06% |
| State Street Corp | 2.73% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue was $605.1 million, down from $626.4 million in Q3 2025. • Q3 net loss was $26.9 million, or $0.15 per diluted sh | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $605.1 million, down 3% year-over-year from $626.4 million. • Net loss was $26.9 million, or $0.15 | 2026-10-28 |
| Board / officer change · Q3 2026 TELADOC HEALTH, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this filing BUSINESS & SEGMENT HIGHLIGHTS • Teladoc He | 2026-09-25 |
| Board / officer change · Q3 2026 TELADOC HEALTH, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Michael Grasher hired as Chief Financial Officer, effective August 31, 2026 • Annual base | 2026-08-31 |
| Board / officer change · Q3 2026 TELADOC HEALTH, INC. – FORM 8-K SUMMARY OTHER NOTABLE POINTS • Board Member Departure: David B. Snow, Jr. notified the company on August 10, 2026 of | 2026-08-13 |
| Board / officer change · Q3 2026 TELADOC HEALTH, INC. - FORM 8-K SUMMARY Filed August 3, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Teladoc Health appointed Mark V. Anquillare as a n | 2026-08-03 |
| Quarterly report · Q2 2026 TELADOC HEALTH, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (Q2 2026): $606.9 million vs. $631.9 million (Q2 2025) — decline of 4.0 | 2026-07-30 |
| Results announced · Q3 2026 TELADOC HEALTH INC. - Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $606.9 million, down 4% year-over-year • Q2 2026 net loss: $38.9 m | 2026-07-29 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Teladoc Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.